Cycle view
- Bloc
- Organization
- Theory
- Practical
- Others
- Credits
| Code | Details | Bloc | Organization | Theory | Practical | Others | Credits |
|---|---|---|---|---|---|---|---|
| PHIN2034-1 | Biotechnologies | B1 | TA | 7 | |||
| Concepts and production of protein and oligonucleotide biopharmaceuticals
David Vermijlen
| 15 | - | - | ||||
| Living biopharmaceuticals, vaccines and biosecurity
Véronique Fontaine
| 6 | - | - | ||||
| Managing the risk of the release of cell and genetic products | 3 | - | - | ||||
| Formulation of biopharmaceuticals
Rita Vanbever
| 15 | - | - | ||||
| Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part A | 5 | - | - | ||||
| Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part B (post-translational modifications)
Cédric Delporte
| 3 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part a: Patents and industrial protection
Patrick Di Stefano
| 5 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part b: Statutes and regulatory constraints on biological products
Hugues Malonne
| 3 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part c: Procedure for releasing batches and the legal framework of vaccines
Lorenzo Tesolin
| 1 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part d: Organisation of quality assurance
Thierry Pronce
| 3 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part e: Introduction to Biobanking | 3 | - | - | ||||
| PHIN2004-1 | Active substances | B1 | TA | 4 | |||
| Substances issues de recherches pharmacochimiques, part a | 10 | - | - | ||||
| Substances issues de recherches pharmacochimiques, part b
François Dufrasne
| 5 | - | - | ||||
| Substances d'origine naturelle, part a
Joëlle Leclercq
| 5 | - | - | ||||
| Substances d'origine naturelle, part b
Caroline Stevigny
| 5 | - | - | ||||
| Produits radiopharmaceutiques
Zena Wimana
| 10 | - | - | ||||
| PHIN2008-2 | Clinical viewpoints | B1 | TA | 5 | |||
| Métabolisme des médicaments et paramètres pharmacocinétiques
François-Xavier Mathy
| 20 | - | - | ||||
| Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) | 15 | - | - | ||||
| Information et pharmacovigilance | 10 | - | - | ||||
| PHIN2013-2 | Quality assurance and pharmaceutical management | B1 | TA | 7 | |||
| Principles of pharmaceutical management
Jean-Michel Vanderhofstadt
| 10 | - | - | ||||
| Quality assurance, part a: basic concepts and quality assurance organisation
Thierry Pronce
| 18 | - | - | ||||
| Quality assurance, part b: analytical technology of procedures and risk analysis
Xavier Marcelis
| 10 | - | - | ||||
| English applied to the pharmaceutical industry
Jacques Poupaert, Nevin Serbest
| 20 | - | - | ||||
| Pharmaceutical marketing | 7,5 | - | - | ||||
| PHIN2033-1
| Pharmaceutical technology | B1 | TA | 5 | |||
| Industrial pharmaceutical microbiology
Véronique Fontaine
| 9 | - | - | ||||
| Preformulation and selection of galenical forms
Jonathan Goole
| 15 | - | - | ||||
| Industrial production of galenical forms | 15 | - | - | ||||
| Industrial aspects of technological development including packaging | 10 | - | - | ||||
| PHIN2023-1 | Drug analysis | B1 | TA | 6 | |||
| Analytical control practices and pharmaceutical and biopharmaceutical control - part a
Pierre Van Antwerpen
| 7 | - | - | ||||
| Analytical control practices and pharmaceutical and biopharmaceutical control - part b | 5 | - | - | ||||
| Pharmaceutical and biopharmaceutical analytical methods - Approving and certifying equipment | 12 | - | - | ||||
| Pharmaceutical and biopharmaceutical analytical methods - Process Analytical Technology | 5 | - | - | ||||
| Statistical methods applied to the pharmaceutical industry
Laure Elens
| 15 | - | - | ||||
| Experimental planning and quality by design | 10 | - | - | ||||
| PHIN2029-2 | Regulation and the medical-social environment | B1 | TA | 8 | |||
| Economic aspects of drug development | 10 | - | - | ||||
| Legislation and procedures applied to pharmaceutical industry - part a: Leglislation
Catherine Druez
| 10 | 5 | - | ||||
| Legislation and procedures applied to pharmaceutical industry - part b: Patents and industrial protection
Patrick Di Stefano
| 5 | - | - | ||||
| Macroeconomic environment and pharmaco-economics
Hugues Malonne
| 10 | - | - | ||||
| CTD File (Common Technical Document) | 15 | - | - | ||||
| Regulations of preclinical and clinical studies: Pharmaceutical toxicological files
Karen Van Malderen
| 15 | - | - | ||||
| Regulations of preclinical and clinical studies: Clinical studies
Anne Lenaers
| 5 | - | - | ||||
| Regulations of preclinical and clinical studies: Pediatric studies
Thierry Schurmans
| 2,5 | - | - | ||||
| Specific regulatory issues, part a: medicine and herbal dietary supplement | 5 | - | - | ||||
| Specific regulatory aspects, part b: Preformulation and documentation of galenic development
Francis Vanderbist
| 5 | - | - | ||||
| Belgian and European legislation on clinical trials | 5 | - | - | ||||
| PHIN2032-1 | Visits and seminars organised in the pharmaceutical industry - [75h Visit]
François Dufrasne, Marianne Fillet, Joëlle Leclercq, Rita Vanbever
| B1 | TA | - | - | [+] | 3 |
| MTFE2000-1 | End-of-course work carried out during an internship in the pharmaceutical industry or in a university research lab - [12w Stage de contact]
François Dufrasne, Philippe Hubert, Joëlle Leclercq
| B1 | TA | - | - | [+] | 15 |